Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

Atopic Dermatitis Clinical Trial

Official title:

A Single (Assessor) Blinded, Randomized, Parallel-group, Monotherapy Trial to Evaluate the Pharmacokinetic and Safety of Tralokinumab in Children (Age 2 to <12 Years) With Moderate-to-severe Atopic Dermatitis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05388760
• Other study ID #: LP0162-1335
• Secondary ID: 2021-005573-12U1
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 7, 2022
• Est. completion date: September 30, 2025

Study information

• Verified date: October 2023
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for treating atopic dermatitis (AD) in children. The trial will last up to 88 weeks, and there will be up to 40 visits, 13 of which may be conducted via telephone if appropriate. The visits will typically be every second week. The first part of the trial is called a screening period and will last between 2 and 6 weeks. After the screening period, the trial drug will be adminstered to the child by subcutaneous (SC) injection. The treatment period with tralokinumab is divided in 2 parts: 1.) initial treatment period for 16 weeks and 2.) open-label treatment period for 52 weeks. The last part of the trial is called a safety follow-up period where the child is of the drug for 14 weeks. All children will use an emollient twice daily (or more) for at least 14 days prior to start of treatment and will continue this treatment throughout the trial. If medically necessary, rescue treatment for AD is allowed at the discretion of the trial doctor.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: September 30, 2025
• Est. primary completion date: August 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 11 Years

Eligibility

Inclusion Criteria:

• Diagnosis of AD (as defined by Hanifin and Rajka criteria for AD).
• Age 2 to <12 years.
• Body weight at baseline:
• =9 kg for children aged 2 to <6 years at screening
• =17 kg for children aged 6 to <12 years at screening.
• History of AD for:
• = 3 months for children aged 2 to <6 years at screening.
• = 12 months for children aged 6 to <12 years at screening.
• History of TCS and/or TCI treatment failure (due to inadequate response or intolerance) or subjects for whom these topical AD treatments are medically inadvisable.
• AD involvement of =10% body surface area at screening and baseline.
• An EASI score of =16 at screening and at baseline.
• An Investigator's Global Assessment (IGA) score of =3 at screening and at baseline.
• Emollient twice daily (or more) for at least 14 days prior to baseline.

Exclusion Criteria:

• Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment.
• Treatment with topical PDE-4 inhibitor within 2 weeks prior to randomization.
• Treatment with the following immunomodulatory medications or bleach baths within 4

weeks prior to baseline:

• Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, JAK inhibitors).
• Systemic corticosteroid use (excludes topical, inhaled, ophthalmic, or intranasal delivery).
• 3 or more bleach baths during any week within the 4 weeks.
• Receipt of any marketed biological therapy or investigational biologic agents

(including immunoglobulin, anti-IgE, or dupilumab):

• Any cell-depleting agents, including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
• Other biologics (including dupilumab): within 3 months or 5 halflives, whichever is longer, prior to baseline.
• Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals, or antiprotozoals within 2 weeks before the baseline visit.
• History of malignancy at any time before the baseline visit.
• History of anaphylaxis following any biological therapy.
• History of immune complex disease.
• Active or suspected endoparasitic infections.
• History of past or current tuberculosis or other mycobacterial infection.
• Established diagnosis of a primary immunodeficiency disorder.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• Tralokinumab
A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment).

Locations

Country	Name	City	State
Czechia	LEO Pharma Investigational Site	Brno
Czechia	LEO Pharma Investigational Site	Praha
France	LEO Pharma Investigational Site	Reims	Ardennes
Netherlands	LEO Pharma Investigational Site	Rotterdam
Netherlands	LEO Pharma Investigational Site	Utrecht
Spain	LEO Pharma Investigational Site	Alicante
Spain	LEO Pharma Investigational Site	Cádiz	Andalucía
Spain	LEO Pharma Investigational Site	Esplugues de Llobregat	Barcelona
Spain	LEO Pharma Investigational Site	Madrid
Spain	LEO Pharma Investigational Site	Madrid
United Kingdom	Leo Pharma Investigational Site	London
United Kingdom	Leo Pharma Investigational Site	Manchester	Greater Manchester
United Kingdom	LEO Pharma Investigational Site	Sheffield

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Countries where clinical trial is conducted

Czechia,  France,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ctrough (trough concentration)		at Week 16
Primary	Cmax (maximum serum concentration)		between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)
Primary	AUC (area under the curve)		between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)
Primary	Tmax (time to maximum serum concentration)		between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)
Secondary	Number of treatment-emergent adverse events in the initial treatment period	An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.	Week 0-Week 16
Secondary	Anti-drug antibodies (status) in the initial treatment period		Week 0-Week 16
Secondary	Number of treatment-emergent adverse events in the open-label treatment period	An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.	Week 16-Week 68
Secondary	Anti-drug antibodies (status) in the open-label treatment period		Week 16-Week 68
Secondary	Change in Scoring Atopic Dermatitis (SCORAD)	The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis (AD) lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.	from Week 0-Week 68
Secondary	Change in Patient-Oriented Eczema Measure (POEM)	The POEM is a validated questionnaire used to assess disease symptoms in atopic eczema patients in both clinical practice and clinical trials (30, 31). The tool consists of 7 items each addressing a specific symptom (itching, sleep, bleeding, weeping, cracking, flaking, and dryness). POEM for proxy completion is used, where the caregiver will report their perception of how often the subject has experienced each symptom over the previous week on a 5-point categorical response scale (0 = 'no days'; 1 = '1 to 2 days'; 2 = '3 to 4 days'; 3 = '5 to 6 days'; 4 = 'every day'). The total score is the sum of the 7 items (range 0 to 28) and reflects disease-related morbidity; a high score is indicative of a worse disease severity.	from Week 0-Week 68
Secondary	Change in Eczema Area and Severity Index (EASI)	The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition.	from Week 0-Week 68